Business Wire

ExaGrid Named “Recommended” Solution for Deduplication Backup Target Appliances by DCIG


ExaGrid ®, a leading provider of hyper-converged secondary storage (HCSS) for backup with data deduplication, today announced that independent analyst firm DCIG once again ranked the ExaGrid disk-based backup appliance in the top category of “Recommended” in its recently published 2018 Deduplication Backup Target Appliance Buyer’s Guide. This body of research assists organizations in matching their business and technical requirements for disk-based backup to best available products.

“This is the fourth consecutive year that ExaGrid has earned top-most positions in the DCIG Buyer’s Guides, which continues to validate the power of our differentiated product architecture and the speed and reliability it delivers,” said Bill Andrews, CEO of ExaGrid. “We’re very proud of this continued distinction.”

DCIG’s analysts concluded that ExaGrid’s unique architecture that combines a landing zone and full appliances in a single scale-out system differentiates its solution from those of its competitors. According to Jerome Wendt, President & Lead Analyst at DCIG, “Enterprises need faster, more scalable, easier to manage deduplication backup target appliances that also accelerate recoveries than ever before. The ExaGrid EX40000E and EX32000, ranked as ‘Recommended’ in the DCIG 2018 Deduplication Backup Target Appliance Buyer’s Guide, exemplify these requirements. ExaGrid’s solutions provide enterprises with the features they need to meet and exceed their backup and recovery requirements while delivering the scalability and simplicity they expect.”

According to the report, ExaGrid’s scale-out architecture, unique landing zone, ongoing virtualization enhancements, and seamless deployments helped the EX40000E and EX32000E appliances place in the top category of “Recommended.” ExaGrid, with its scale-out backup storage and unique landing zone, is 3 times faster for ingest and over 20 times faster for restores and VM boots than its closest competitor. In addition, ExaGrid is the only solution that provides a fixed-length backup window as data grows. With ExaGrid, IT can have the fastest backups, restores, and VM boots; a fixed-length backup window; and the ability to easily scale their systems, so they simply buy what they need as they need it, all at the lowest cost up front and over time. ExaGrid eliminates forklift upgrades and product obsolescence.

The DCIG 2018 Deduplication Backup Target Appliance Buyer’s Guide drives time and cost out of the product selection process by enabling prospective buyers to more quickly identify a shortlist of products that meet their specific needs. Thus, prospective purchasers can focus their product evaluation energies and move more quickly to buying the best solution for them.

About DCIG
DCIG is a group of analysts with IT industry expertise who provide informed, insightful, third party analysis and commentary on IT hardware, software and services. DCIG independently develops and licenses access to DCIG Buyer's Guide Editions. DCIG Buyer's Guides provide actionable intelligence through comprehensive, in-depth analysis of data center infrastructure product features. DCIG also develops sponsored content in the form of blog entries, customer validations, product reviews, special reports and executive, standard and full-length white papers. DCIG's target audiences include C-level executives, IT managers, systems and storage engineers and architects, press/media, magazine and website editors, bloggers, financial and technical analysts, and cloud service providers. More information is available at .

About ExaGrid

ExaGrid provides hyper-converged secondary storage for backup with data deduplication, a unique landing zone, and scale-out architecture. ExaGrid’s landing zone provides for the fastest backups, restores, and instant VM recoveries. Its scale-out architecture includes full appliances in a scale-out system and ensures a fixed-length backup window as data grows, eliminating expensive forklift upgrades. Follow us @ExaGrid and LinkedIn, and visit See what ExaGrid customers have to say about their own ExaGrid experiences and why they now spend significantly less time on backup.

ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.

Contact information

Christine Murphy, 508-898-2872 x248

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Seoul Semiconductor’s SunLike Series LEDs Win Product of the Year Award from Elektronik Magazine23.3.2018 18:28Pressemelding

Seoul Semiconductor, a global innovator of LED products and technology, announced on March 23rd that its SunLike Series natural spectrum LED product won the Gold Award at the Elektronik Product of the Year 2018 Awards, hosted by Elektronik (, a leading German electronics publication. This press release features multimedia. View the full release here: Product of the Year Award from Elektronik Magazine (SunLike) (Photo: Business Wire) As a publication specializing in electrical and electronic components, “Elektronik” is a prestigious magazine with an illustrious history and the largest number of subscribers in Germany. Over the past 20 years, they have conducted annual surveys among their subscribers to find the “most creative and innovative products.” Based on these survey results, Elektronik selects the top product that with the most impact in its corresponding field, and confers the awards accordingl

Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance23.3.2018 16:05Pressemelding

Elliott Advisors (UK) Limited (“Elliott”), which advises funds which collectively hold a significant economic interest in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), welcomes the proposed governance reforms announced by Bezeq last night. In its initial letter to Bezeq Interim Chairman David Granot, dated January 16, 2018, Elliott outlined the urgent need to address the Company’s serious corporate governance issues, and called for changes at the Board level that result in “the right mixture of expertise, independence and integrity for the future.” Elliott stated then, and reiterates now, its belief that “there is significant value to be unlocked if the right steps are taken to improve its corporate governance.” Bezeq has strong business fundamentals, an exemplary workforce, and great potential. Following yesterday’s announcement, Elliott highlights the changes that have occurred since January 16th. Taken together, these amount to a revolution in the

Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 12:52Pressemelding

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal

CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 12:50Pressemelding

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation

Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 12:46Pressemelding

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c

Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 12:00Pressemelding

Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at This press release features multimedia. View the full release here: Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on